

November 30, 2023

Dear Prader-Willi Syndrome Community,

We are pleased to share that we have [initiated](#) the pivotal Phase 3 COMPASS PWS study of carbetocin nasal spray (ACP-101) in the United States. COMPASS PWS is a 12-week study evaluating the efficacy and safety of carbetocin nasal spray for hyperphagia in approximately 170 children and adults aged 5 to 30 years with Prader-Willi syndrome.

At this time, about 36 clinical study sites throughout the United States, Canada and Europe are expected to participate in the Phase 3 COMPASS PWS study. Participants who complete the Phase 3 study will be eligible to enroll in a long-term, open-label extension study designed to investigate the safety and tolerability of long-term treatment with carbetocin nasal spray.

For more information on the COMPASS PWS study, including who can participate, please visit the trial website at CompassPWS.com. The website also features a “Find a Research Site” tool which will be updated on an ongoing basis as trial sites are opened.

If you have questions about the carbetocin nasal spray Phase 3 study, please contact us at medicalinformation@acadia-pharm.com. We are inspired by your unwavering commitment to your loved ones and we are dedicated to pursuing this investigational treatment to address a severely unmet need for those living with Prader-Willi syndrome and their families.

Thank you for your continued support.

All our best,
The Acadia Prader-Willi Syndrome Team